IHC was conducted as described previously [48 (link)]. Following primary antibodies were used: anti-pan cytokeratin (1:200, pan-CK, NB120-6401, Novus biological, Littleton, CL, USA), anti-epidermal growth factor receptor (1:30, EGFR, sc-03, Santa Cruz, Santa Cruz, CA, USA), and anti-Ki-67 (1:500, NCL-Ki-67p, Novocastra laboratories, Newcastle upon Tyne, UK).
Free full text: Click here